Screener
UroGen Pharma URGN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
FAQ
- What is UroGen Pharma's cash & equivalents?
- UroGen Pharma (URGN) reported cash & equivalents of $79.13M in Q2 2026.
- How has UroGen Pharma's cash & equivalents changed year-over-year?
- UroGen Pharma's cash & equivalents decreased by 14.8% year-over-year, from $92.9M to $79.13M.
- What is the long-term trend for UroGen Pharma's cash & equivalents?
- Over 5 years (2020 to 2025), UroGen Pharma's cash & equivalents has grown at a 15.9% compound annual growth rate (CAGR), from $52.86M to $110.75M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about UroGen Pharma's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude